---
title: "福泰制药宣布其在肾脏产品组合方面取得关键进展"
description: "9 月 25 日（路透社）- Vertex Pharmaceuticals Inc：Vertex 宣布肾脏产品组合的关键进展 Vertex Pharmaceuticals Inc：FDA 授予 povetacicept 在 IgA 肾病中的突破性疗法认定 Vertex Pharmaceuticals Inc - 预计将在 2026 年上半年申请美国的加速批准"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/258887961.md"
published_at: "2025-09-25T12:35:35.000Z"
---

# 福泰制药宣布其在肾脏产品组合方面取得关键进展

> 9 月 25 日（路透社）- Vertex Pharmaceuticals Inc：Vertex 宣布肾脏产品组合的关键进展 Vertex Pharmaceuticals Inc：FDA 授予 povetacicept 在 IgA 肾病中的突破性疗法认定 Vertex Pharmaceuticals Inc - 预计将在 2026 年上半年申请美国的加速批准

Sept 25 (Reuters) - Vertex Pharmaceuticals Inc:

-   Vertex announces key advancements across kidney portfolio
-   Vertex Pharmaceuticals Inc: FDA granted breakthrough therapy designation for povetacicept in IgA nephropathy
-   Vertex Pharmaceuticals Inc - on track to file for accelerated approval in U.S. in H1 2026

### Related Stocks

- [VRTX.US - 福泰制药](https://longbridge.com/zh-CN/quote/VRTX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Significant opportunities exist in the global pain market for novel mechanisms and modalities | The global pain market presents significant opportunities for innovation, particularly in developing non-addictive alter | [Link](https://longbridge.com/zh-CN/news/275921122.md) |
| Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit | Sionna Therapeutics presented its strategy for developing next-generation cystic fibrosis therapies focused on NBD1 stab | [Link](https://longbridge.com/zh-CN/news/276001201.md) |
| Newron Pharmaceuticals startet Phase-III-Studie mit Evenamide bei therapieresistenter Schizophrenie | Newron Pharmaceuticals S.p.A. has announced the release of clinical data on Evenamide, a novel glutamate modulator being | [Link](https://longbridge.com/zh-CN/news/274605134.md) |
| Health Canada Accepts Cipher Pharmaceuticals' Natroba Submission for Review | Cipher Pharmaceuticals Inc. announced that Health Canada has accepted its new drug submission for Natroba™ (Spinosad), a | [Link](https://longbridge.com/zh-CN/news/273997136.md) |
| How Is The Market Feeling About Vertex Pharmaceuticals Inc? | Vertex Pharmaceuticals Inc's short interest has decreased by 3.54%, with 4.29 million shares sold short, representing 1. | [Link](https://longbridge.com/zh-CN/news/272313190.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。